Keratinocyte growth factor therapy in murine oleic acid-induced acute lung injury
Authors:
- M. SternMSM. Stern
- M. E. GoddardMGM. E. Goddard
- J. WilliamsJWJ. Williams
- J. ZhuJZJ. Zhu
- A. DewarADA. Dewar
- H. A. PainterHPH. A. Painter
- P. K. JefferyPJP. K. Jeffery
- D. R. GillDGD. R. Gill
- S. C. HydeSHS. C. Hyde
- D. M. GeddesDGD. M. Geddes
- M. TakataMTM. Takata
- 1 June 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 288 (6) , L1179-L1192
Abstract
Alveolar type II (ATII) cell proliferation and differentiation are important mechanisms in repair following injury to the alveolar epithelium. KGF is a potent ATII cell mitogen, which has been demonstrated to be protective in a number of animal models of lung injury. We have assessed the effect of recombinant human KGF (rhKGF) and liposome-mediated KGF gene delivery in vivo and evaluated the potential of KGF as a therapy for acute lung injury in mice. rhKGF was administered intratracheally in male BALB/c mice to assess dose response and time course of proliferation. SP-B immunohistochemistry demonstrated significant increases in ATII cell numbers at all rhKGF doses compared with control animals and peaked 2 days following administration of 10 mg/kg rhKGF. Protein therapy in general is very expensive, and gene therapy has been suggested as a cheaper alternative for many protein replacement therapies. We evaluated the effect of topical and systemic liposome-mediated KGF-gene delivery on ATII cell proliferation. SP-B immunohistochemistry showed only modest increases in ATII cell numbers following gene delivery, and these approaches were therefore not believed to be capable of reaching therapeutic levels. The effect of rhKGF was evaluated in a murine model of OA-induced lung injury. This model was found to be associated with significant alveolar damage leading to severe impairment of gas exchange and lung compliance. Pretreatment with rhKGF 2 days before intravenous OA challenge resulted in significant improvements in Po2, Pco2, and lung compliance. This study suggests the feasibility of KGF as a therapy for acute lung injury.Keywords
This publication has 67 references indexed in Scilit:
- Keratinocyte Growth Factor Pretreatment Is Associated with Decreased Macrophage Inflammatory Protein-2?? Concentrations and Reduced Neutrophil Recruitment in Acid Aspiration Lung InjuryShock, 2002
- Transfer of Heme Oxygenase 1 cDNA by a Replication-Deficient Adenovirus Enhances Interleukin 10 Production from Alveolar Macrophages That Attenuates Lipopolysaccharide-Induced Acute Lung Injury in MiceHuman Gene Therapy, 2001
- Sequential Injection of Cationic Liposome and Plasmid DNA Effectively Transfects the Lung with Minimal Inflammatory ToxicityMolecular Therapy, 2001
- Interleukin-10 Gene Therapy-Mediated Amelioration of Bacterial PneumoniaInfection and Immunity, 2000
- In vivo expression of neutrophil inhibitory factor via gene transfer prevents lipopolysaccharide-induced lung neutrophil infiltration and injury by a beta2 integrin-dependent mechanism.Journal of Clinical Investigation, 1998
- Keratinocyte growth factor attenuates lung leak induced by alpha-naphthylthiourea in ratsCritical Care Medicine, 1996
- Modulation of keratinocyte growth factor and its receptor in reepithelializing human skin.Journal of Experimental Medicine, 1995
- Intratracheal instillation of keratinocyte growth factor decreases hyperoxia-induced mortality in rats.Journal of Clinical Investigation, 1995
- Increased Immunoreactive Rat Lung Icam-1 in Oleic Acid-Induced Lung InjuryExperimental Lung Research, 1995
- Sequential cardiopulmonary changes after oleic-acid injury in dogsCritical Care Medicine, 1985